Dolaflexin, Platform, Program, Publications, UpRi (XMT-1536) Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer March, 2022